Trials
2 active
4 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “AlloNK, dosed after a conditioning regimen, combined with Rituximab.”In the company’s words, NCT06991114 on ClinicalTrials.gov
- Tested for
- Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs), Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA, IIM, Myositis, Scleroderma, Sjogren Syndrome and 5 more
- Main trialPhase 2
- “A Basket Trial of Refractory Rheumatoid Arthritis (RA), Sjögren's Disease (SjD), Idiopathic Inflammatory Myopathies (IIMs) and Systemic Sclerosis (SSc) subjects to evaluate the safety and efficacy of AlloNK, a non-genetically modified allogeneic NK cell, in combination with rituximab.”In the company’s words, NCT06991114 on ClinicalTrials.gov
- Other names
- Allogeneic NK Cells
Other drugs for Systemic Sclerosis (SSc)
- AnifrolumabAstraZeneca · Phase 3
- AdmilparantBristol Myers Squibb · Phase 3
- BMS-986353Bristol Myers Squibb · Phase 3
- CABA-201Cabaletta Bio · Phase 2/3
- BelimumabGSK · Phase 3
- NerandomilastBoehringer Ingelheim · Phase 3
Coming up2
- Aug 2027Phase 1 trial completes · ClinicalTrials.gov
- Jan 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Jan 2028 | AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases. | |
| Phase 1Active, not recruiting | Aug 2027 | AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus | |
| Phase 2Terminated | 7 Nov 2024 | Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL | |
| Phase 1/2Completed | 6 Oct 2025 | AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026